Regulation of membrane type-matrix metalloproteinases

Seminars in Cancer Biology

Volumn 12, Issue 2, 2002, Pages 131-138

  Hernandez Barrantes, Sonia ^a   Bernardo, Margarida ^a   Toth, Marta ^a   Fridman, Rafael ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Matrix metalloproteinases; Proteases; Stroma; Tumor invasion

Indexed keywords

MATRIX METALLOPROTEINASE; ENZYME PRECURSOR; METALLOPROTEINASE;

ANGIOGENESIS; CANCER INVASION; CELL MOTILITY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; METASTASIS; MOLECULAR INTERACTION; PROTEIN DEGRADATION; PROTEIN PROCESSING; REGULATORY MECHANISM; REVIEW; TUMOR CELL; CELL MEMBRANE; CHEMISTRY; DRUG ANTAGONISM; ENZYME ACTIVATION; ENZYMOLOGY; HUMAN; METABOLISM; NEOPLASM;

CELL MEMBRANE; ENZYME ACTIVATION; ENZYME PRECURSORS; HUMANS; MATRIX METALLOPROTEINASES, MEMBRANE-ASSOCIATED; METALLOENDOPEPTIDASES; NEOPLASMS;

EID: 0035999155     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1006/scbi.2001.0421     Document Type: Article

References (76)

1. Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis
2. ECM and cell surface proteolysis: Regulating cellular ecology
3. Tumor and stromal expression of matrix metalloproteinases and their role in tumor progression
4. A matrix metalloproteinase expressed on the surface of invasive tumour cells
5. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease
6. Identification of the second membrane-type matrix metalloproteinase (MT-MMP-2) gene from a human placenta cDNA library. MT-MMPs form a unique membrane-type subclass in the MMP family
7. cDNA sequence and mRNA tissue distribution of a novel human matrix metalloproteinase with a potential transmembrane segment
8. Molecular cloning of a novel membrane-type matrix metalloproteinase from a human breast carcinoma
9. Identification and characterization of the fifth membrane-type matrix metalloproteinase MT5-MMP
10. Identification and characterization of human MT5-MMP. A new membrane-bound activator of progelatinase A overexpressed in brain tumors
11. Human MT6-matrix metalloproteinase: Identification, progelatinase A activation, and expression in brain tumors
12. Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas
13. Roles of membrane type 1 matrix metalloproteinase and tissue inhibitor of metalloproteinases 2 in invasion and dissemination of human malignant glioma
14. Differential expression of membrane-type matrix metalloproteinase and its correlation with gelatinase A activation in human malignant brain tumors in vivo and in vitro
15. Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human invasive breast carcinomas
16. Role of MT-MMPs and MMP-2 in pancreatic cancer progression
17. Expression of membrane-type matrix metalloproteinase in human gastric carcinomas
18. Increased expression of matrix metalloproteinase 7 and 9 and membrane type 1-matrix metalloproteinase in esophageal squamous cell carcinomas
19. Membrane type 1-matrix metalloproteinase (MT1-MMP) and MMP-2 immunolocalization in human prostate: Change in cellular localization associated with high-grade prostatic intraepithelial neoplasia
20. Membrane-type matrix metalloproteinase-1 expression and activation of gelatinase A as prognostic markers in advanced pediatric neuroblastoma
21. High level of MT-MMP expression is associated with invasiveness of cervical cancer cells
22. Immunohistochemical study of MT-MMP tissue status in gastric carcinoma and correlation with survival analyzed by univariate and multivariate analysis
23. Membrane-type 1 matrix metalloproteinase mRNA expression in colorectal cancer
24. Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human oral squamous cell carcinomas: Implications for lymph node metastasis
25. Clinical significance of MT1-MMP mRNA expression in breast cancer
26. Functional activation of integrin alpha V beta 3 in tumor cells expressing membrane-type 1 matrix metalloproteinase
27. Matrix-dependent proteolysis of surface transglutaminase by membrane-type metalloproteinase regulates cancer cell adhesion and locomotion
28. Membrane-type 1 matrix metalloproteinase cleaves cd44 and promotes cell migration
29. Role of membrane type 1-matrix metalloproteinase and gelatinase A in head and neck squamous cell carcinoma invasion in vitro
30. Regulation of cell invasion and morphogenesis in a three-dimensional type I collagen matrix by membrane-type matrix metalloproteinases 1, 2, and 3
31. Regulation of membrane-type-1 matrix metalloproteinase activity by its cytoplasmic domain
32. Functional characterization of MT3-MMP in transfected MDCK cells: Progelatinase A activation and tubulogenesis in 3-D collagen lattice
33. Expression of membrane-type matrix metalloproteinase 1 (MT1-MMP) in tumor cells enhances pulmonary metastasis in an experimental metastasis assay
34. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins
35. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase 1
36. Transmembrane/cytoplasmic domain-mediated membrane type 1-matrix metalloprotease docking to invadopodia is required for cell invasion
37. Mutation analysis of membrane type-1 matrix metalloproteinase (MT1-MMP). The role of the cytoplasmic tail Cys-574, the active site Glu-240 and furin cleavage motifs in oligomerization, processing and self-proteolysis of MT1-MMP expressed in breast carcinoma cells
38. Matrix metalloproteinases: Structures, evolution, and diversification
39. Structural properties of matrix metalloproteinases
40. Membrane type 4 matrix metalloproteinase (MT4-MMP, MMP-17) is a glycosylphosphatidylinositol-anchored proteinase
41. Membrane-type 6 matrix metalloproteinase (MT6-MMP, MMP-25) is the second glycosyl-phosphatidyl inositol (GPI)-anchored MMP
42. Transmembrane-deletion mutants of the membrane-type matrix metalloproteinase-1 process progelatinase A and express intrinsic matrix-degrading activity
43. Activation of a recombinant membrane type 1-matrix metalloproteinase (MT1-MMP) by furin and its interaction with tissue inhibitor of metalloproteinases (TIMP)-2
44. Regulation of membrane type-1 matrix metalloproteinase activation by proprotein convertases
45. Membrane type matrix metalloproteinase 1 activates pro-gelatinase A without furin cleavage of the N-terminal domain
46. The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation. Regulation by TIMP-2 and TIMP-3
47. Membrane-type-2 matrix metalloproteinase can initiate the processing of progelatinase A and is regulated by the tissue inhibitors of metalloproteinases
48. Characterization of a truncated recombinant form of human membrane type 3 matrix metalloproteinase
49. Tissue inhibitor of metalloproteinases-4 inhibits but does not support the activation of gelatinase A via efficient inhibition of membrane type 1-matrix metalloproteinase
50. Membrane type 4 matrix metalloproteinase (MMP17) has tumor necrosis factor-alpha convertase activity but does not activate pro-MMP2
51. Catalytic activities of membrane-type 6 matrix metalloproteinase (MMP25)
52. Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases
53. Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules
54. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover
55. Membrane-type 1 matrix metalloprotease (MT1-MMP) enables invasive migration of glioma cells in central nervous system white matter
56. Tissue inhibitor of metalloproteinase-2 (TIMP-2) binds to the catalytic domain of the cell surface receptor, membrane type 1-matrix metalloproteinase 1 (MT1-MMP)
57. The TIMP2 membrane type 1 metalloproteinase 'receptor' regulates the concentration and efficient activation of progelatinase A. A kinetic study
58. Intermolecular autolytic cleavage can contribute to the activation of progelatinase A by cell membranes
59. Analysis of tissue inhibitor of metalloproteinases-2 effect on pro-matrix metalloproteinase-2 activation by membrane-type 1 matrix metalloproteinase using baculovirus/insect-cell expression system
60. Human tissue inhibitor of metalloproteinases 3 interacts with both the N- and C-terminal domains of gelatinases A and B. Regulation by polyanions
61. Differential roles of TIMP-4 and TIMP-2 in pro-MMP-2 activation by MT1-MMP
62. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3
63. Claudin promotes activation of Pro-MMP-2 mediated by membrane-type matrix metalloproteinases
64. Cellular mechanisms for human procollagenase-3 (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase A (MMP-2) are able to generate active enzyme
65. Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas
66. Proteolytic processing of membrane-type-1 matrix metalloproteinase is associated with gelatinase A activation at the cell surface
67. The activation of ProMMP-2 (gelatinase A) by HT1080 fibrosarcoma cells is promoted by culture on a fibronectin substrate and is concomitant with an increase in processing of MT1-MMP (MMP-14) to a 45 kDa form
68. Binding of active (57 kDa) membrane type 1-matrix metalloproteinase (MT1-MMP) to tissue inhibitor of metalloproteinase (TIMP)-2 regulates MT1-MMP processing and pro-MMP-2 activation
69. Expression of three membrane-type matrix metalloproteinases (MT-MMPs) in rat vascular smooth muscle cells and characterization of MT3-MMPs with and without transmembrane domain
70. Shedding of membrane type 1 matrix metalloproteinase in a human breast carcinoma cell line
71. Tissue inhibitor of metalloproteinase (TIMP)-2 acts synergistically with synthetic matrix metalloproteinase (MMP) inhibitors but not with TIMP-4 to enhance the (Membrane type 1)-MMP-dependent activation of pro-MMP-2
72. High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma
73. Protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in papillary thyroid carcinomas
74. High levels of TIMP-2 correlate with adverse prognosis in breast cancer
75. Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumor recurrence
76. Expression of tissue inhibitor of matrix metalloproteinase-2 correlates with activation of matrix metalloproteinase-2 and predicts poor prognosis in tongue squamous cell carcinoma